Ranbaxy Laboratories, received the final approval in Canada to manufacture and market Ran-Simvastatin tablets from Health Canada, Therapeutic Products Directorate. The total generic market size of Simvastatin tablets in Canada is $CAD153 million.
Ranbaxy has got the approval for Ran-Simvastatin in 5, 10, 20 and 40 mg strengths, through its wholly-owned subsidiary Ranbaxy Pharmaceuticals- Canada Inc (RPCI), Gurgaon-based (RPCI) said in a statement.
“We look forward to marketing this organically developed product in all strengths that will be commercialised at an affordable price. Ran-Simvastatin represents the second approval granted to RPCI in July,” said Paul Drake, President RPCI.
On Monday, the Pharmaceutical firm had received approval from the Canadian drug regulator TPD to market and manufacture 'Ran-Amlodipine tablets', used in treating hypertensions.
